Form 4: Svetlana Lucas Acquires 15,000 Stock Options in Jasper Therapeutics

Director Svetlana Lucas acquired 15,000 stock options in Jasper Therapeutics on June 18, 2024, according to a Form 4 filing.

Summary

• Svetlana Lucas, a director of Jasper Therapeutics, Inc. [JSPR], filed a Form 4 on June 20, 2024.
• The filing reports a transaction that occurred on June 18, 2024, where Lucas acquired 15,000 stock options.
• The exercise price of the stock options is $23.19.
• The options vest over a four-year period, with 1/4th vesting on June 18, 2025, and the remaining 1/48th vesting monthly thereafter, contingent upon continuous service.
• Following the transaction, Lucas directly owns 15,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of options by a director is mildly positive, suggesting confidence, but it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies a multi-year commitment from the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates changes in beneficial ownership by a company insider.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates